Xeris Biopharma Holdings
XERS
199 hedge funds and large institutions have $481M invested in Xeris Biopharma Holdings in 2025 Q1 according to their latest regulatory filings, with 56 funds opening new positions, 73 increasing their positions, 39 reducing their positions, and 18 closing their positions.
355% more call options, than puts
Call options by funds: $2.44M | Put options by funds: $537K
211% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 18
116% more capital invested
Capital invested by funds: $222M → $481M (+$259M)
87% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 39
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
23% more funds holding
Funds holding: 162 → 199 (+37)
12.93% more ownership
Funds ownership: 43.98% → 56.9% (+13%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$6.82M |
| 2 |
Morgan Stanley
New York
|
+$5.69M |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$5.59M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
+$5.45M |
| 5 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$4.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$8.73M |
| 2 |
CC
Caxton Corporation
Princeton,
New Jersey
|
-$6.83M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$3.51M |
| 4 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
-$2.46M |
| 5 |
CP
CenterBook Partners
Greenwich,
Connecticut
|
-$880K |
XERS Hedge Fund Activity: Q1 2025 in Review
199 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q1 2025, worth a combined $481M — up 116% from $222M a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new XERS positions and 18 closed out — a net gain of 38 holders — while 73 added to existing stakes and 39 trimmed.
The largest buyer was D.E. Shaw & Co, adding an estimated $6.82M. The largest seller was AIGH Capital Management, exiting entirely with an estimated $8.73M sold.
- 199 institutional investors held Xeris Biopharma Holdings (XERS) as of Q1 2025, up from 162 in Q4 2024.
- Funds reported $481M of Xeris Biopharma Holdings stock for Q1 2025, up 116% quarter-over-quarter.
- 56 funds opened new Xeris Biopharma Holdings positions in Q1 2025 and 18 closed out, a net change of +38 holders.
- The largest Xeris Biopharma Holdings buyer in Q1 2025 was D.E. Shaw & Co, an estimated $6.82M added.
- The largest Xeris Biopharma Holdings seller in Q1 2025 was AIGH Capital Management, an estimated $8.73M sold.
Based on aggregated 13F filings for Q1 2025.